Stock CRMD CORMEDIX INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages CorMedix Inc.

Equities

CRMD

US21900C3088

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
5.37 USD -2.72% Intraday chart for CorMedix Inc. +3.47% +42.82%
04-15 CorMedix's DefenCath Now Commercially Available For US Inpatient Use MT
04-15 CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin)
Sector Update: Health Care Stocks Decline Late Afternoon
CorMedix to Supply to DefenCath to Florida-based Dialysis Organization
CorMedix Inc. Announces Commercial Agreement with ARC Dialysis, LLC
Sector Update: Health Care Stocks Ease Wednesday Afternoon
CorMedix Remains Encouraged on DefenCath Opportunity, RBC Says
CorMedix Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CorMedix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CorMedix Inc. Updates Related to Its Business and Anticipated Launch of DefenCath
Cormedix Inc. Announces Commercial and Operational Updates
CorMedix Inc. Approves the Separation of Employment of Phoebe Mounts
CorMedix Inc. Announces the Appointment of Beth Zelnick Kaufman, Esq. as Executive Vice President, Chief Legal Officer, and Corporate Secretary, Effective December 12, 2023
CorMedix Inc. Announces Partnership with The Leapfrog Group
Sector Update: Health Care Stocks Mixed Late Afternoon
Sector Update: Health Care Stocks Mixed Wednesday Afternoon
Sector Update: Health Care
CorMedix Inc. Announces FDA Approval of DefenCath(R) to Reduce the Incidence of Catheter Related Bloodstream Infections in Adult Hemodialysis Patients
CorMedix's DefenCath Approved by US FDA; Shares Jump
U.S. FDA approves CorMedix's antimicrobial drug
CorMedix Q3 Net Loss Steady; Sees Cash Position Sufficient to Fund Operations for 12 Months
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRMD Stock
  4. News CorMedix Inc.
  5. Other languages